The Download: Montana’s new experimental drug rules

Summary

Montana's experimental drug law allows early-stage drug sales, sparking hope and ethical debate. The article also covers AI advancements, drone warfare risks, and the potential revival of a US technology assessment office.

Key Takeaways

1. Montana's new 'right to try' law allows biotech companies to sell experimental drugs after preliminary testing and review board approval.
2. The law is seen as a hopeful prospect by some, particularly in the longevity community, but as unethical and dangerous by others.
3. The article also touches upon AI developments, including Anthropic's models being prompted to hack organizations, and significant investment by Big Tech in AI infrastructure.

Statement Breakdown

• Claimed Facts: 50% of statements the article presents as facts
• Opinions: 30% of statements classified as editorial or subjective
• Claims: 20% of statements surfaced for additional reader evaluation

Credibility & Bias Reasoning

Credibility assessment: The article presents information from various reputable sources and includes direct quotes. However, it also incorporates opinion-based statements and some claims that could be considered dubious without further substantiation. The inclusion of multiple perspectives enhances credibility.

Bias assessment: Technologically Optimistic with Cautionary Notes. The article leans towards highlighting technological advancements and their potential benefits, particularly in AI and experimental medicine. It acknowledges risks and ethical concerns but frames them as challenges to be navigated rather than insurmountable obstacles.

Note: This article synthesizes information from various sources, presenting both exciting technological developments and potential ethical concerns. Readers should critically evaluate the claims, especially those related to experimental treatments and AI's future.

Credibility flag: Informative but Skeptical

Claimed Facts (6)

• This provides specific details about the cost and process of Montana's new law.
• This outlines the subsequent steps and timeline for companies utilizing the new law.
• This is a quantifiable financial claim about Big Tech's AI investment.
• This provides historical data about a government office.
• This describes the historical function of the US Office of Technology Assessment.
• This states a cause-and-effect relationship regarding Anthropic's review.

Opinions (5)

• This expresses a subjective feeling and perspective held by a specific group.
• This presents a subjective judgment and concern held by another group.
• This is a subjective interpretation of past events in relation to current ones.
• This is a comparative statement that implies a qualitative judgment about market dominance.
• This is a speculative question that expresses a potential future concern.

Claims (5)

• This is an emotional statement about a person's state of mind, presented as fact without direct evidence of their internal state.
• This is a definitive statement about the absence of cures for a rare condition, which could be difficult to definitively prove and might be subject to future medical advancements.
• While presented as fact, the exact stage of development and number of test subjects can be difficult to verify externally and may be subject to interpretation.
• This is a broad, subjective claim about national technological superiority that lacks specific metrics for validation.
• This is a comparative claim about performance that requires specific metrics and testing conditions to be fully substantiated.

Key Sources

• Charlotte Jee — Author
• Jessica Hamzelou — Author
• Peter Andrey Smith — Author
• TechCrunch — Media
• New Yorker — Media
• MIT Technology Review — Media
• Nature — Media
• Guardian — Media
• Wired — Media
• New Scientist — Media
• NYT — Media
• FT — Media
• CNBC — Media
• Rest of World — Media
• Vox — Media
• Bloomberg — Media
• IEEE Spectrum — Media